drugset / Trial / NCT01221831

Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2

NCT01221831

Phase 2 Completed 396 enrolled Estetra
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multi-centre, comparative study in young, healthy, female volunteers of reproductive age. Primary objective: \- To investigate the effect of 2 dosages of estetrol combined with P1 or P2, on vaginal bleeding patterns (cycle control), in comparison with a combined oral contraceptive containing estradiol valerate and dienogest Secondary objectives: * To investigate ovulation inhibition * To investigate the effect on SHBG * To assess pregnancy rate * To evaluate subject satisfaction, dysmenorrhoea, acne, and body weight * To investigate return of menstruation after treatment * To evaluate general safety and acceptability

Timeline

Start
2010-09
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dienogest Small molecule Oral
Subject ESTETROL ANHYDROUS Other / unclassified Oral
Subject P1 Unknown Oral
Subject P2 Unknown Oral
Comparator estradiol valerate Unknown Oral

Indications

No indication recorded.